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Hepatic metastases from a variety of primary human tumours
occur with high frequency, and their presence is usually associated
with a low response rate to conventional systemic chemotherapy
(Anderson et al, 1994). Efforts to establish innovative drug
delivery strategies that improve the efficacy of anti-cancer agents
against liver metastases, therefore, are not only desirable but may
also produce clinical results more rapidly than the development of
new chemical entities (Kim, 1993). Portal vein or hepatic artery
infusion of a cytotoxic agent (Anderson et al, 1994), encapsulation
of drugs in liposomes (Kim, 1993; Anderson et al, 1994) and liver-
targeted erythrocytes (Zocchi et al, 1989) are examples of recently
employed attempts to increase the anti-tumour efficacy of
chemotherapeutic agents against metastatic liver neoplasms.
We previously explored the possibility of using lymphoid cells,
namely cytotoxic T lymphocytes and lymphokine-activated killer
cells (LAK) cells, to carry toxins or cytotoxic drugs to the tumour
site (Cerundolo et al, 1987; Zanovello et al, 1992; Mandruzzato et
al, 1994). As LAK cells are preferentially localized in the host￿s
lungs, liver and spleen following systemic intravenous (i.v.) injec-
tion (Lotze et al, 1980; Maghazachi and Fitzgibbon, 1990), we
addressed the therapeutic effect of i.v. adoptive transfer of drug-
loaded LAK cells in mice bearing lung metastases (Zanovello et
al, 1992; Mandruzzato et al, 1994). We found that when ricin or
iododoxorubicin (IDX), a lipophilic doxorubicin (DX) derivative,
was delivered by LAK cells its efficacy against experimentally
induced lung metastases was increased (Zanovello et al, 1992;
Mandruzzato et al, 1994).
Methoxymorpholinyl doxorubicin (MMDX; PNU 152243) is a
promising, highly lipophilic semisynthetic anthracycline that
shows activity against multidrug-resistant cells both in vitro and in
vivo and is not cardiotoxic at therapeutic doses (Grandi et al, 1990;
Ripamonti et al, 1992; Danesi et al, 1993; Vasey et al, 1995); it is
currently undergoing phase I/II clinical trials. This anti-cancer
drug is biotransformed in the liver into more cytotoxic metabolites
by means of a cytochrome P450-dependent process that can be
simulated in vitro by incubating the drug with liver microsomes in
the presence of NADPH (K￿hl et al, 1993; Lau et al, 1994). This
metabolic potentiation by the hepatic microsomal enzymes may
contribute to rendering MMDX highly active against liver tumour
cell colonies. Preclinical evaluation of MMDX efficacy against
hepatic tumours is not yet available, but a phase I clinical study
reported regressions in patients with liver metastases from
colorectal cancer (Vasey et al, 1995).
Using a mouse liver metastasis model, we evaluated the
possible therapeutic advantage of delivering MMDX encapsulated
in interleukin 2 (IL-2)-activated natural killer (A-NK) cells. We
show here that, in mice bearing hepatic metastases, systemic i.v.
adoptive transfer of A-NK cells encapsulating MMDX exerts a
greater therapeutic effect than the administration of an equivalent
or even higher dose of the drug in free form. Moreover, we
observed a significant survival benefit when drug doses that were
ineffective in free form were instead delivered by A-NK cells.
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Summary The possibility of using interleukin 2 (IL-2)-activated natural killer cells (A-NK) to carry methoxymorpholinyl doxorubicin (MMDX;
PNU 152243) to liver-infiltrating tumours was explored in mice bearing 2-day established M5076 reticulum cell sarcoma hepatic metastases.
In vitro, MMDX was 5.5-fold more potent than doxorubicin against M5076 tumour cells. MMDX uptake by A-NK cells correlated linearly with
drug concentration in the incubation medium [correlation coefficient (r) = 0.999]; furthermore, as MMDX incorporation was readily
reproducible in different experiments, the amount of drug delivered by A-NK cells could be modulated. In vivo experiments showed that
intravenous (i.v.) injection of MMDX-loaded A-NK cells exerted a greater therapeutic effect than equivalent or even higher doses of free drug.
The increase in lifespan (ILS) following A-NK cell delivery of 53 mg kg–1 MMDX, a dosage that is ineffective when administered in free form,
was similar to that observed in response to 92 mg kg–1 free drug, a dosage close to the 10% lethal dose (ILS 42% vs. 38% respectively). These
results correlated with pharmacokinetic studies showing that MMDX encapsulation in A-NK cells strongly modifies its organ distribution and
targets it to tissues in which IL-2 activated lymphocytes are preferentially entrapped after i.v. injection.
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35128 Padova, Italy.MATERIALS AND METHODS
Drugs
MMDX and DX (kindly supplied by Pharmacia & Upjohn as
hydrochloride salts) were dissolved in sterile bidistilled water;
concentrations were checked spectrophotometrically [MMDX lmax
495 nm (CH3OH), E 1% = 173; DX lmax 496 nm (H2O), E 1% =
200] and stock solutions (1 mM of MMDX and 0.8 mM of DX)
were stored at —20°C. All working solutions were also checked by
high-performance liquid chromatography (HPLC) before use.
Animals and tumour cell line
Seven- to nine-week old inbred female C57BL/6 mice (Charles
River, Calco, Italy) were used throughout this study. The mice
were fed standard mouse chow, had free access to water and were
age matched in individual experiments.
M5076 reticulum cell sarcoma, kindly supplied by Dr R
Giavazzi, Mario Negri Institute of Pharmacological Research,
Bergamo, Italy, was maintained in vivo as an ascitic tumour in
syngenic C57BL/6 mice, with transplants every 3 weeks. M5076
tumour cells preferentially metastasize to the liver after i.v. injec-
tion (Hart et al, 1981).
Monitoring of animals during in vivo experiments
Procedure involving animals and their care were in conformity
with institutional guidelines that comply with national and interna-
tional laws and policies (EEC Council Directive 86/609, OJ L 358,
1, Dec. 12, 1987; NIH Guide for the Care and Use of Laboratory
Animals, NIH Publication No. 85-23, 1985).
During in vivo survival experiments, animals in all experi-
mental groups were examined daily for an increase in abdominal
volume, decrease in physical activity and other signs of disease in
order to identify those expected to become moribund within a
short time. Severely ill animals were euthanized by ethyl ether
overdose and then autopsied to verify whether their illness had
been caused by a large tumour burden. Survival time of each
animal was calculated as the number of days elapsed between
tumour inoculation and euthanization.
Generation of A-NK cells
Murine A-NK cells were prepared as previously reported (Gunji et
al, 1989). Briefly, single spleen cell suspensions were prepared in
RPMI-1640 tissue culture medium (Life Technologies, Paisley,
UK) with 3% (v/v) heat-inactivated fetal bovine serum (FBS)
(Flow, Irvine, UK). Erythrocytes were lysed by incubation with
ammonium chloride—potassium buffer solution. The resulting cells
were cultured (37°C, 5% carbon dioxide) with 1000 IU ml—1
human recombinant IL-2 (Proleukin, EuroCetus-Chiron, Milan,
Italy) in complete medium (CM), which consisted of RPMI-1640
supplemented with 10% (v/v) FBS, 2 mM glutamine, 50 mM 2-
mercaptoethanol and antibiotics. After 2 days of incubation, non-
adherent cells were discarded and the culture flasks gently washed
three times with warm (37°C) CM. The plastic adherent cells were
cultured for another 5 days with 1000 U ml—1 human recombinant
IL-2 in fresh CM. After a short treatment with 0.02% EDTA (w/v)
in phosphate-buffered saline (PBS) (Oxoid, Basingstoke, UK) 
A-NK cells were harvested, washed twice with RPMI-1640 with
3% (v/v) FBS, counted and used; cell recovery rate ranged from
30% to 60% of the seeded spleen cells. The A-NK cells obtained
under these experimental conditions were generally 75—90% NK
1.1+, and less than 20% CD3+, as determined by flow cytofluoro-
metric analysis with appropriate antibodies, and demonstrated
high lytic activity against both LAK-susceptible P815 masto-
cytoma and M5076 tumour cells (not shown).
Evaluation of M5076 tumour cell chemosensitivity
MMDX and DX inhibition of M5076 cell growth in vitro was
assessed by a slightly modified MTT colorimetric assay as previ-
ously described (K￿hl et al, 1993). Per cent survival was calcu-
lated from the absorbance (A) values as follows: survival (%) =
(A)tested — Ablank)/(Auntreated control — Ablank) ´ 100, with Ablank referring to
the absorbance of wells that contained only medium and MTT.
Drug concentrations that decreased survival by 50% (IC50 values)
were calculated from semilogarithmic dose—response curves by
linear interpolation.
Evaluation of MMDX uptake and release by A-NK cells
A-NK cells (5 ´ 106 ml—1) were incubated with different concentra-
tions of MMDX at 37°C for 30 min in RPMI-1640 supplemented
with 3% (v/v) FBS. MMDX influx was stopped by rapidly chilling
the tubes to 4°C, and extracellular drug was removed by
centrifuging the cells through a layer of horse serum (HS) (Gibco,
Life Technologies, Paisley, UK). Cells were then washed once
with ice-cold RPMI-1640, aliquoted, centrifuged and their drug
content was determined.
To evaluate in vitro drug release, cells (5 ´ 106 ml—1) were incu-
bated with 600 nM MMDX at 37°C for 30 min, processed as
above, aliquoted, resuspended in drug-free HS and incubated at
37°C for various fixed time intervals. Samples were then rapidly
chilled to 4°C, washed once with ice-cold RPMI 1640, centrifuged
and their MMDX content evaluated. Each determination was
made in quadruplicate.
The amount of intracellular MMDX was determined by HPLC
as previously reported for IDX (Mandruzzato et al, 1994) and
expressed as ng MMDX 10—6 cells.
Induction and therapy of liver metastases
Weight-matched mice were injected with M5076 cells (5 ´ 104
viable cells per mouse) in their tail vein. Two days later, the
animals were weighed and randomly assigned to one of the
following protocols: i.v. injection of in vitro MMDX-treated A-
NK cells; i.v. injection of different amounts of free MMDX in a
volume of 0.2 ml PBS; or i.v. injection of only PBS (control mice).
In some experiments, an additional experimental group received
an i.v. injection of untreated A-NK cells. MMDX doses were
based on mean body weight (s.d. never exceeded 0.50 g). The
number of MMDX-treated A-NK cells injected varied from 15 to
30 ´ 106 per mouse, depending on the number of cells recovered
from the different cultures; the drug concentration in the incuba-
tion medium thus ranged from 200 to 600 nM in order to load the
A-NK cells with the desired amount of MMDX. For every batch of
MMDX-loaded cells, an aliquot was evaluated for MMDX content
by HPLC. In one set of experiments, mice were killed 21 days
after the tumour cell injection; livers were harvested, rinsed in
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counted with the aid of a dissecting microscope. A second set of
experiments measured survival time after tumour injection/treat-
ment as described above. Treatment efficacy was evaluated by
comparing median survival time (MST) in the treated and control
groups, and expressed as ILS as follows:
ILS(%) = (100 ´ MST of treated mice/MST of control mice) — 100
The MST of control animals ranged from 24 to 30 days. Treatment
was considered ineffective when ILS < 20%.
Bone marrow toxicity
MMDX was administered either as free drug or encapsulated in A-
NK cells to weight-matched healthy mice on a mean body weight
basis. Retro-orbital sinus blood samples were collected on days 3,
7 and 11 following drug administration (six mice per experimental
group), diluted with 10 mM EDTA, and counted with a haemo-
cytometer after lysis of red blood cells with acidified methyl violet
solution [5% acetic acid (v/v)]. White blood cell (WBC) counts
were expressed as a percentage of mean value obtained from
control mice that received PBS only.
Drug biodistribution studies
MMDX was administered i.v. either as free drug or encapsulated
in A-NK cells to weight-matched mice on a mean body weight
basis. At 15, 90 and 150 min, three mice in each treatment group
were sacrificed by excess ethyl ether anaesthesia. The liver, spleen
and lungs were rapidly excised, thoroughly washed in 0.9%
sodium chloride solution and frozen in liquid nitrogen. MMDX
was extracted as follows: 2—2.5 ml of distilled water was added to
the samples, which were homogenized using an Ultra Turrax appa-
ratus; 0.5 ml of 33% silver nitrate was added to the homogenate,
which was then mixed vigorously for 20 min at 4°C; 5 ml of ethyl
acetate—n-butanol (9:1) was added, and the mixture was further
shaken for 10 min at 4°C; samples were then spun at 6000 r.p.m.
for 10 min and the organic phase was recovered. The extraction
procedure was repeated twice, and the two resulting organic
phases were dried in a Braun alpha 4 evaporator. Dried samples
were recovered with 0.5 ml of methanol, sonicated for 30 s and
spun at 13 000 g for 10 min at 4°C. The amount of MMDX in the
supernatants was evaluated by HPLC analysis as previously
reported for IDX (Mandruzzato et al, 1994) and expressed as ng of
MMDX per g of tissue. The mean recovery of the drug from
different organs ranged from 67% to 87%, with 95% repro-
ducibility.
Statistical analysis
Statistical analysis was performed using the GraphPad InStat
computer program (GraphPad Software, San Diego, CA, USA)
and the Mann—Whitney U-test.
RESULTS
MMDX uptake and release by A-NK cells
Preliminary experiments compared M5076 tumour cell sensitivity
to MMDX and DX; cells were incubated with different drug
concentrations for 48 h at 37°C, and cell survival was evaluated by
an MTT colorimetric assay. The potency ratio (ratio of the IC50
value for DX vs. the IC50 value for MMDX) was 5.5 (not shown).
This result agrees with reports regarding the in vitro sensitivity of
other murine and human tumour cell lines to MMDX and DX
(Grandi et al, 1990; K￿hl et al, 1993; Lau et al, 1994).
The kinetics of MMDX uptake by A-NK cells was biphasic,
with an initial phase of rapid uptake (first 15 min) followed by a
steady-state phase (not shown). By fixing the incubation time at
30 min, a linear relationship between the MMDX concentration in
the incubation medium and its uptake by A-NK cells emerged
(Figure 1). Moreover, the amount of MMDX incorporated by the
A-NK cells was highly reproducible in several experiments, prob-
ably because of the homogeneity in the size of A-NK cells (Melder
et al, 1988; Bouwens et al, 1992). Thus, by varying the MMDX
concentration in the incubation medium during cell loading, we
could modify the amount of drug delivered by A-NK cells to the
tumour-bearing animals.
Analysis of the time course of drug efflux from MMDX-treated
A-NK cells revealed that cellular MMDX contents decreased
quickly to about 55% within 15 min post incubation; this initial
phase of rapid efflux was followed by a second one in which the
efflux rate was much slower. A representative experiment is shown
in Figure 2. We observed a similar biphase kinetics of drug efflux
from IDX-loaded standard LAK cells (Mandruzzato et al, 1994).
Encapsulation in A-NK cells increases anti-tumour
activity of MMDX
The anti-tumour activity of MMDX administered via A-NK cells
or in free form was evaluated in terms of tumour reduction and
animal survival. In the first set of experiments, the mice were
sacrificed on day 21, and the surface hepatic tumour nodules were
counted. Mice that had received MMDX delivered by A-NK cells
had significantly fewer nodules than mice administered an equiva-
lent amount of free drug. A representative experiment is reported
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Figure 1 MMDX uptake by A-NK cells as a function of exposure
concentration. Cells (5 ´ 106 ml–1) were incubated with different
concentrations of MMDX for 30 min at 37°C. After rapid chilling at 4°C, cells
were harvested, centrifuged through a layer of HS and washed once with
RPMI-1640. MMDX intracellular content was evaluated by HPLC as
described in Materials and methods. Each determination was made in
quadruplicate. Points, mean of at least three separate experiments; bars, s.d.
The line represents the linear regression equation. Correlation coefficient
was 0.999in Table 1. Treatment with 52 mg kg—1 MMDX encapsulated in A-
NK cells induced a significantly greater reduction in the number of
tumour nodules than the administration of 51 mg kg—1 free drug;
this reduction was similar to that observed in animals receiving 92
mg kg—1 MMDX in free form, a dose close to 10% lethal dose
(LD10). Furthermore, unlike the animals that received 51 mg kg—1
MMDX in free form, 90% of the mice treated with MMDX-loaded
A-NK cells were free of visible liver metastases on day 21.
No tumour reduction was observed in experiments in which
mice bearing 2-day established M5076 hepatic metastases were
injected i.v. with 15—30 ´ 106 untreated A-NK cells without
concomitant injection of IL-2 (not shown).
To determine whether the reduction in the number of liver
metastases after adoptive transfer of MMDX-loaded A-NK cells
translated into a prolonged survival time, the MSTs of the experi-
mental groups receiving either free or cell-associated MMDX
were compared with that of the control group, and treatment effi-
cacy was expressed as per cent ILS. Some experiments included
an additional test group consisting of mice receiving untreated A-
NK cells alone. As shown in Table 2, treatment with MMDX-
loaded A-NK cells was more effective in prolonging survival than
the administration of an equivalent or even greater amount of free
drug. As seen in experiment II (Table 2), 52 mg kg—1 free MMDX
was ineffective, but 53 mg kg—1 MMDX delivered by A-NK cells
granted an ILS equivalent to that afforded by 92 mg kg—1 free drug.
The administration of untreated A-NK cells or very low doses of
A-NK cell-bound or free MMDX did not modify survival of
tumour-bearing mice (experiment I, Table 2).
To determine the effects of free or A-NK cell-associated
MMDX on haematopoiesis, WBC counts were examined in
healthy mice on days 3, 7 and 11 following drug administration. At
all investigated time points, WBC counts of mice treated with
55 mg kg—1 A-NK cell-bound MMDX were only moderately
depressed (Figure 3). In contrast, mice receiving 92 mg kg—1 free
drug showed a marked myelosuppression on days 7 and 11 (65%
and 53% depression of WBC counts respectively).
In vivo MMDX distribution is modified by encapsulation
in A-NK cells
To investigate whether the therapeutic effect observed in mice
receiving MMDX-loaded A-NK cells was related to an increased
drug uptake by the liver, we compared the tissue distribution of
MMDX injected in free form with that of MMDX encapsulated in
A-NK cells. Mice were injected with either 58 mg kg—1 MMDX
encapsulated in A-NK cells, or 80 mg kg—1 free MMDX, the lowest
drug dose conferring a similar therapeutic effect. Moreover, a
group of mice also received 150 mg kg—1 free MMDX, a toxic dose
producing 100% mortality (not shown). At 15, 90 and 150 min
after i.v. injection, three animals per group were killed and drug
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Figure 2 Time course of drug efflux from MMDX-loaded A-NK cells. Cells
(5 ´ 106 ml–1) were incubated with 600 nM MMDX for 30 min at 37°C. After
rapid chilling at 4°C, cells were harvested, centrifuged, washed once with
RPMI-1640 and then resuspended in drug-free HS. At each indicated time-
point, four samples were processed to evaluate their MMDX content by
HPLC as described in Materials and methods. Points, mean; bars, s.d.
Table 1 Effect of MMDX on M5076 reticulum cell sarcoma growth in the liver
Group Treatmenta MMDX dose Liver metastasis- Median no. (range) of  Statistical comparison of metastasis 
(mg kg–1) bearing mice liver metastases number with groupb
A PBS (control) – 10/10 137.5 (47–> 250) B (P < 0.05); C, D, E (P < 0.0001)
B Free MMDX 41 10/10 16.5 (8–135)
C Free MMDX 51 9/10 3.5 (0–12) D (P = 0.001); E (P = 0.0003)
D Free MMDX 92 2/9c 0 (0–1) E (P = 0.66)
E MMDX-loaded A-NK cellsd 52 1/10 0 (0–1)
aOn day 0, C57BL/6 mice were injected i.v. with 5 ´ 104 M5076 tumour cells. Two days later, they were weighed, randomly assigned to an experimental group
(n = 10) and received i.v. MMDX either in free form or encapsulated in A-NK cells; control group mice received only PBS. The mice were killed on day 21, and
liver metastatic nodules counted with the aid of a dissecting microscope. bTwo tailed Mann–Whitney test. cOne mouse out of ten died on day 7. d30 ´ 106 A-NK
cells pretreated with 300 nM MMDX for 30 min at 37°C.
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Figure 3 Myelosuppression studies in healthy C57BL/6 mice given free or
A-NK cell-bound MMDX. On day 0, mice received a single i.v. injection of
PBS, free MMDX or 27 ´ 106 A-NK cells pretreated with 300 nM MMDX for
30 min at 37°C. Samples of retro-orbital sinus blood obtained on days 3, 7
and 11 were processed as described in Materials and methods. WBC counts
were expressed as a percentage of values obtained from control animals.
Columns, mean (n = 6); bars, s.d.concentration in liver, spleen and lungs was determined by HPLC.
Results are summarized in Figure 4. Fifteen minutes after treat-
ment, drug levels in the livers of mice injected with 58 mg kg—1
MMDX encapsulated in A-NK cells were very similar to those
observed in animals treated with 80 mg kg—1 free drug, and lower
than those in mice receiving 150 mg kg—1 free drug. At 90 min,
however, levels in mice receiving MMDX encapsulated in A-NK
cells were much higher than those in mice administered 80 mg kg—1
free MMDX, and close to those observed in mice treated with 
150 mg kg—1 free drug. Similarly, at 150 min, drug levels were
higher in mice receiving 58 mg kg—1 MMDX via A-NK cells,
compared with 80 mg kg—1 in free form.
MMDX concentrations in the spleens of animals receiving
MMDX-loaded A-NK cells were very low at 15 min after treat-
ment, and less than those detected in mice injected with free drug.
However, spleen drug concentrations progressively increased in
animals treated with MMDX-loaded A-NK cells, and after
150 min were higher than those observed in mice treated with
150 mg kg—1 free MMDX.
The distribution of MMDX was quite different in lungs; 15 min
after injection its level in mice that received MMDX-loaded A-NK
cells was about 1.7-fold higher than that observed in animals
injected with 150 mg kg—1 free MMDX. This high organ concentra-
tion rapidly decreased, and at 150 min after injection reached a
value similar to that observed in animals receiving 80 mg kg—1 free
MMDX.
DISCUSSION
We previously demonstrated that i.v. injection of IDX-loaded LAK
cells exerted a greater therapeutic effect than an equivalent amount
of free drug in mice bearing experimentally induced lung
metastases; this effect was largely due to the persistent high drug
levels reached in the lungs following delivery by LAK cells
(Mandruzzato et al, 1994). The distinctive feature of this chemo-
immunotherapeutic approach is that tissue drug concentrations are
determined mainly by the distribution pattern of the transferred
cytotoxic cells, which are primarily trapped in the lungs following
Delivery of methoxymorpholinyl doxorubicin by A-NK cells 1071
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Table 2 Effect of MMDX on life span in mice bearing M5076 hepatic metastases
Group Treatmenta MMDX dose (mg kg–1) ILSb (%) Statistical comparison with groupc
Experiment I A PBS (control) – B (P = 0.97); C (P = 0.85); D (P = 0.24); E (P = 0.43)
B Untreated A-NK cellse –0
C Free MMDX 28 0 E (P = 0.11)
D Free MMDX 55 13d E (P = 0.73)
E MMDX-loaded A-NK cellse 21 10d
Experiment II F PBS (control) – G (P = 0.07); H (P = 0.012); I (P = 0.0009); J (P = 0.001)
G Free MMDX 41 10d
H Free MMDX 52 17d J (P = 0.005)
I Free MMDX 92 38 J (P = 0.94)
J MMDX-loaded A-NK cellsf 53 42
Experiment III K PBS (control) – L, M, N (P < 0.0001)
L Free MMDX 75 48 N (P = 0.0034); M (P = 0.97)
M Free MMDX 84 50 N (P = 0.0044)
N MMDX-loaded A-NK cellsg 76 70
aOn day 0, C57BL/6 mice were injected i.v. with 5 ´ 104 M5076 tumour cells. Two days later they were weighed, randomly assigned to an experimental group
(n = 10–15) and received i.v. injection of PBS, untreated A-NK cells, free MMDX or MMDX-treated A-NK cells. The animals were observed daily in order to
determine their survival time. bCalculated as (100 ´ MST of treated mice/MST of control mice) –100. cTwo-tailed Mann–Whitney test. dTreatment was considered
ineffective when ILS <20%. e21 ´ 106 A-NK cells incubated in the presence (group E) or absence (group B) 300 nM MMDX for 30 min at 37°C. f27.5 ´ 106 A-NK
cells pretreated with 300 nM MMDX for 30 min at 37°C. g22.5 ´ 106 A-NK cells pretreated with 500 nM MMDX for 30 min at 37°C.
58 mg kg–1 MMDX encapsulated in A-NK cells
80 mg kg–1 free MMDX


































Figure 4 Drug levels in liver, spleen and lung after i.v. injection of free
MMDX or MMDX-loaded A-NK cells. Weight-matched C57BL/6 mice
received i.v. MMDX in free form or encapsulated in A-NK cells (15.5 ´ 106 A-
NK cells pretreated with 600 nM MMDX for 30 min at 37°C). At the different
time points, three mice per experimental group were sacrificed; the liver,
spleen and the lungs were rapidly excised, weighed and processed for drug
content evaluation as described in Materials and methods. Columns, mean of
three mice per experimental group; bars, s.d.systemic i.v. injection and then migrate to the liver and spleen
(Lotze et al, 1980; Maghazachi and Fitzgibbon, 1990). On the
basis of these findings, the present study explored the possibility
of curing tumours localized in the liver by administering via A-NK
cells a novel anthracycline, MMDX, which is characterized by a
wide spectrum of anti-neoplastic activity and whose enzymatic
transformation in the liver produces highly cytotoxic metabolites.
A-NK cells, initially referred to as adherent lymphokine-acti-
vated killer cells, are cytotoxic lymphocytes endowed with a large
granular lymphocyte morphology, an NK phenotype and a higher
in vitro and in vivo anti tumour activity as compared with conven-
tional LAK cells (Melder et al, 1988; Gunji et al, 1989; Schwarz et
al, 1989). Furthermore, in vitro expansion of A-NK cells is gener-
ally faster than that of LAK cells, despite a strong interindividual
variation in the proliferation rate, particularly in A-NK cells gener-
ated from peripheral blood lymphocytes of patients with cancer
(Melder et al, 1988). By using A-NK cells, we could overcome the
major drawback of the previously proposed experimental proce-
dure, i.e, the high variability in drug incorporation by in vitro IL-2-
activated lymphocytes (Mandruzzato et al, 1994). Indeed, the
higher homogeneity in the size of the A-NK cells obtained at the
end of the culture period resulted in a high reproducibility of
MMDX uptake and a linear correlation between drug concentra-
tion in the incubation medium and its accumulation in A-NK cells
(Figure 1). Therefore, by using A-NK cells, the amount of MMDX
delivered by carrier cells to tumour-bearing animals could be
modulated with high precision.
The adoptive transfer of MMDX-loaded A-NK cells in mice
bearing hepatic metastases led to a drastic decrease in the number
of tumour nodules. Indeed, a count of the visible liver metastases
21 days after the tumour cell injection disclosed that treatment
with 50—60 mg kg—1 MMDX delivered by A-NK cells exerted a
strong therapeutic effect. As seen in the representative experiment
reported in Table 1, only one of ten mice receiving 52 mg kg—1
MMDX via A-NK cells developed a single neoplastic nodule in
the liver, whereas nine of ten mice receiving a similar amount of
free MMDX exhibited single or even multiple metastases; a
similar reduction in the number of hepatic tumour nodules was
achieved in response to a dose of free MMDX that was about twice
that delivered by A-NK cells, and close to LD10. Moreover, in mice
receiving MMDX-loaded A-NK cells, the reduction in the number
of metastatic liver nodules observed on day 21 translated into a
significantly greater prolongation of the survival time, in compar-
ison with mice injected with a similar amount of free drug.
The critical finding of this study is that a significant survival
benefit is obtained when drug doses that are ineffective or margin-
ally effective in free form are instead delivered by A-NK cells.
Pharmacokinetic studies explain this therapeutic effect by showing
that MMDX encapsulation in A-NK cells alters its tissue distribu-
tion, and targets it to those organs in which A-NK cells are preferen-
tially retained after i.v. injection. At all the time points investigated,
drug levels in the liver tissue of mice receiving 58 mg kg—1 MMDX
encapsulated in A-NK cells were similar to or even higher than
those of mice receiving 80 mg kg—1 free MMDX, which is the lowest
free drug dose able to grant a therapeutic effect in terms of tumour
reduction, and also an ILS similar to that observed in response to
50—60 mg kg—1 MMDX delivered via A-NK cells. The accumulation
of MMDX-loaded A-NK cells in the liver, and the subsequent slow
MMDX efflux may be mainly responsible for the observed
enhanced anti-tumour effect. The slow drug release from MMDX-
loaded A-NK cells entrapped in the spleen, an organ whose
venous blood is drained through the portal vein system, may also
contribute to the therapeutic effect in this tumour model. Indeed,
considering the high drug level reached in the spleen at 150 min
after injection, this contribution might be substantial.
That the intrinsic anti-tumour activity of A-NK cells might
contribute to the observed therapeutic effect after administration
of MMDX-loaded A-NK cells could be excluded, as a single i.v.
infusion of untreated A-NK cells at the doses employed in this
study (15—30´106 cells per mouse), without concomitant adminis-
tration of IL-2, neither decreased the number of liver metastatic
nodules on day 21 (not shown) nor affected the survival of tumour-
bearing mice (Table 2, experiment I). Furthermore, the in vitro
cytolytic activity of MMDX-treated A-NK cells 4 h after incuba-
tion with the drug was only about 40% of controls, albeit no cell
membrane alterations, as judged by the eosin dye exclusion test,
were observed at this time (not shown).
Myelosuppression represents the dose-limiting toxicity of
MMDX (Vasey et al, 1995). Experiments in which the bone
marrow toxicity of 55 mg kg—1 MMDX delivered by A-NK cells
was compared with that of 92 mg kg—1 free MMDX, a drug dose
that showed a similar therapeutic efficacy in hepatic metastases-
bearing mice, disclosed that the former induced only a moderate
decrease of peripheral WBC counts at all the investigated time
points; 92 mg kg—1 free MMDX instead produced a marked
haematological toxicity resulting in a 65% depression of WBC
counts on day 7 (Figure 3).
In conclusion, by means of our delivery system, a therapeutic
effect against murine hepatic metastases could be achieved at an
MMDX dosage that did not produce significant myelotoxicity.
This approach could possibly increase the clinical utility of this
chemotherapeutic agent in patients with hepatic neoplasms.
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